Quoin Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
QNRX Quoin Pharmaceuticals Ltd
INDP Indaptus Therapeutics Inc
RNAZ Transcode Therapeutics Inc
NEOV NeoVolta Inc
SYBX Synlogic Inc
FIISO Financial Institutions Inc
KA Kineta Inc
TCS Container Store Group Inc
MLGO MicroAlgo Inc
INDI indie Semiconductor Inc

Health Care : Biotechnology |
Based in Israel
Company profile

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
Day's Change
-0.30 (-6.00%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Rivian stock jumps nearly 6% as EV maker narrows quarterly loss, keeps guidance intact

5:31 pm ET May 9, 2023 (MarketWatch)

By Claudia Assis

Rivian's better-than-expected results cap difficult first quarter for EV startups

Shares of Rivian Automotive Inc. rose nearly 6% in the aftermarket Tuesday after the electric-vehicle maker reported a narrower quarterly loss and kept intact its guidance for the year.

Rivian (RIVN) lost $1.35 billion, or $1.45 a share, in the first quarter, compared with a loss of $1.6 billion, or $1.77 a share, in the year-ago period. Adjusted for one-time items, Rivian lost $1.25 a share.

Revenue jumped to $661 million, from $95 million a year ago, when it delivered fewer than 2,000 vehicles. Analysts polled by FactSet expected Rivian to report an adjusted loss of $1.62 a share on sales of $664 million.

Rising production in the quarter meant that Rivian was able to spread out factory fixed costs, Chief Executive RJ Scaringe said on a call with analysts after the report. That pickup in pace also was "crucial" to realizing the long-term structural-cost advantages of the company's vertically integrated strategy, he said.

"While challenges remain, we've become a stronger, more agile company through this process," Scaringe said.

Rivian reaffirmed its production outlook of 50,000 vehicles for the year, saying that was based on "our latest understanding of the supply-chain environment."

"We continue to believe the supply chain will continue to be the main limiting factor of our (Normal, Ill.) facility output," the Rivian executives said in a letter to shareholders. "Our team continues to work on the introduction of new engineering design changes and key technologies which will take effect during the second half of 2023 to help mitigate anticipated supply-chain constraints."

Chief Financial Officer Claire McDonough said on the call that Rivian remained "confident" that it has enough cash to fund operations through 2025 and that it has strengthened its balance sheet in preparation for the launch of a cheaper, new-generation EV platform, the R2, in 2026.

See also:Fisker cuts production guidance, posts wider loss than expected

Rivian's intact guidance contrasted with outlook cuts for Fisker Inc. (FSR) and Lucid Group Inc. (LCID) this week.

Earlier Tuesday, Fisker reported a wider-than-expected first-quarter loss and said it expects to produce 32,000 to 36,000 vehicles in 2023, including 1,400 to 1,700 in the second quarter.

When it reported fourth-quarter earnings in February, Fisker guided for production of "up to 42,400 units" in the year.

And late Monday, Lucid Group reported steeper quarterly losses and cut its guidance for the year to "more than" 10,000 vehicles, from a previous guidance of between 10,000 and 14,000 vehicles.

Don't miss:Lucid stock drops 9% after EV startup dials down production guidance

Shares of Rivian have lost 40% in the past 12 months, contrasting with gains of about 3.3% for the S&P 500 index . The stock is down 16% so far this year, versus an advance of around 7.4% for the S&P 500.

-Claudia Assis

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 09, 2023 17:31 ET (21:31 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.